Comparative Tolerability of the HMG-CoA Reductase Inhibitors
- 1 January 2000
- journal article
- research article
- Published by Springer Nature in Drug Safety
- Vol. 23 (3) , 197-213
- https://doi.org/10.2165/00002018-200023030-00003
Abstract
The availability of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors has revolutionised the treatment of lipid abnormalities in patients at risk for the development of...Keywords
This publication has 59 references indexed in Scilit:
- Concomitant use of cytochrome P450 3A4 inhibitors and simvastatinThe American Journal of Cardiology, 1999
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- HMG CoA Reductase Inhibitor-Induced Myotoxicity: Pravastatin and Lovastatin Inhibit the Geranylgeranylation of Low-Molecular-Weight Proteins in Neonatal Rat Muscle Cell CultureToxicology and Applied Pharmacology, 1997
- Range of serum cholesterol values in the population developing coronary artery diseaseThe American Journal of Cardiology, 1995
- Central Nervous System Effects of HMG CoA Reductase Inhibitors: Lovastatin and Pravastatin on Sleep and Cognitive Performance in Patients with HypercholesterolemiaThe Journal of Clinical Pharmacology, 1994
- Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin.Journal of Clinical Pathology, 1993
- Expanded clinical evaluation of lovastatin (EXCEL) study results II. Assessment of the human lens after 48 weeks of treatment with lovastatinThe American Journal of Cardiology, 1991
- Lens changes in matched normals and hyperlipidemic patients treated with simvastatin for 2 yearsActa Ophthalmologica, 1990
- Efficacy and long-term adverse effect pattern of lovastatinThe American Journal of Cardiology, 1988
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987